ACCESS Newswire
12 May 2022, 23:43 GMT+10
MILAN, ITALY / ACCESSWIRE / May 12, 2022 / Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today a €3.5 million seed investment in NanoPhoria, a pre-clinical stage biotech company that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles.
The investment was made through the Sofinnova Telethon Fund, the venture capital firm's early-stage strategy focused mainly on investments in rare and genetic diseases, and the largest fund entirely dedicated to biotechnology in Italy.
The lead product coming out of the platform is a treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide.
Nanophoria was co-founded by Dr. Daniele Catalucci, Research Director at the Institute of Genetic and Biomedical Research (IRGB), National Research Council (CNR); Dr. Michele Iafisco, Senior Researcher at the Institute of Science and Technology for Ceramics (ISTEC), National Research Council; Dr. Alessio Alogna, Cardiologist and Clinical Scientist at Charité Universitätsmedizin Berlin; and the CEO, Claudio De Luca, a life science executive with more than 25 years of experience in leadership positions in medtech and biotech
'NanoPhoria is developing a cutting-edge approach for a non-viral delivery of biologics, targeted to the heart, and can count on a team of four co-founders whose skills are complimentary, with scientific, medical and industrial experience,' said Lucia Faccio, a Partner with the Sofinnova Telethon Fund. 'They are all actively involved in the management of the company.'
The company, whose versatile platform allows selective targeting at the organ and/or cellular level, has been officially recognized as a spin-off of CNR, the largest multidisciplinary public research institution in Italy.
NanoPhoria will be presenting at the upcoming BioEquity conference, Europe's premier meeting of investors and biopharma executives, which will take place in Milan from May 16-18.
'We are pleased to have the support of Sofinnova Telethon Fund as we work to consolidate our nano-delivery platform and advance our first product towards the clinic,' said Claudio De Luca, CEO and co-founder of NanoPhoria. 'Our collaboration has already proved very positive. It will
strongly contribute to the acceleration of our development programs and help us bring effective therapies to patients and address unmet clinical needs.'
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
About NanoPhoria
NanoPhoria is a biotech company based in Milan that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles. The company's first product is a pre-clinical stage treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide. The company, whose four founders have active roles and complimentary backgrounds, is a spin-off from CNR, the largest public research institution in Italy.
Media Contacts
NanoPhoria
Daniele Catalucci, Chief Scientific Officer
[email protected]
Havas PR Milan
Pierluigi Cavarai
[email protected]
+39 (0) 392 7799933
SOURCE: Sofinnova Partners
Get a daily dose of Irish Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Irish Sun.
More InformationWASHINGTON, D.C.: Industry leaders are pushing the Trump administration to clear regulatory obstacles slowing the rollout of self-driving...
NEW YORK, New York – Israeli military forces caused deaths and unnecessary suffering of Palestinian patients while occupying hospitals...
BRUSSELS, Belgium: The European Union is set to tighten steel import quotas starting in April, reducing inflows by 15 percent to prevent...
WASHINGTON, D.C.: U.S. Transportation Secretary Sean Duffy has warned that New York's Metropolitan Transportation Authority (MTA) could...
WASHINGTON, D.C.: Commerce Secretary Howard Lutnick said the Trump administration is asking companies and foreign governments to help...
Israel Air Force pilots have bombed a funeral in northern Gaza, killing more than a dozen mourners. Family and friends of Dr Wasim...
BRUSSELS, Belgium: The European Union is set to tighten steel import quotas starting in April, reducing inflows by 15 percent to prevent...
DUBLIN, Ireland: Ireland's property prices continued their upward trend, rising by 8.1 percent in the 12 months leading to January...
BERLIN, Germany: Audi has announced plans to cut up to 7,500 jobs in Germany by 2029 as part of a broader restructuring aimed at reducing...
FRANKFURT, Germany: UBS CEO Sergio Ermotti will receive a pay package of just over 15 million Swiss francs (US$17 million) for 2024,...
DUBLIN, Ireland: Dublin came alive with energy and color as thousands lined the streets to celebrate St. Patrick's Day, soaking in...
DUBLIN, Ireland: Authorities in two border counties have spent over 1.6 million euros in the past five years cleaning up toxic waste...